美股异动 | 礼来涨超2%，减肥药对比实验力压诺和诺德
本周三（12月4日），礼来减肥药Zepbound在首次对比试验中超越诺和诺德的Wegovy，美股盘初涨超2%，截至发稿报830.26美元：
在礼来最新赞助的研究中，接受Zepbound治疗的受试者经过72周的治疗后，平均体重减轻了20.2%，而接受Wegovy治疗的受试者平均体重减轻了13.7%。
礼来的这项新研究是首个随机临床试验，证明在直接对比测试中，Zepbound能够诱导比Wegovy更多的体重减轻。
实验结果公布后， 诺和诺德 盘前跌超0.6%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10